Hydrophobic surfactant effects on aortic cholesterol accumulation and atherosclerosis in hypercholesterolemic rabbits.
Studies were performed in hypercholesterolemic rabbits to determine whether the hydrophobic surfactant, Poloxalene 2930 (Pol), is of benefit under these conditions. Lipoprotein analyses plus chemical and morphologic studies of the aorta were performed to evaluate the results. In one study, rabbits were made hypercholesterolemic by dietary means and then divided into two groups and given a cholesterol-free diet with one group additionally given Pol with treatment continued for 10 weeks. Pol treatment resulted in less atherosclerosis but the mechanism for this effect was not apparent from lipoprotein analysis. In the other study 3 groups of rabbits were given a cholesterol-rich diet for 16 weeks. Two groups received Pol supplement with one of these groups receiving a dose that was too small to prevent hypercholesterolemia. In this group plus the group on diet alone comparable degrees of hypercholesterolemia were maintained throughout the study. Lipoprotein abnormalities were similar in these two groups except that those on Pol had a more normal cholesterol to apolipoprotein B ratio. The amount of atherosclerosis in both groups was mild but aortic cholesterol content was much less for the Pol group. It is concluded that Pol limits cholesterol accumulation in the aortic wall of hypercholesterolemic rabbits and can retard the development of atherosclerosis.
D000818:Animals; D001011:Aorta / Q000378:metabolism*; D001055:Apolipoproteins B / Q000097:blood; D001161:Arteriosclerosis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood / Q000378:metabolism*; D002791:Cholesterol, Dietary / Q000494:pharmacology; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008297:Male; D010743:Phospholipids / Q000097:blood; D011060:Poloxalene / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011817:Rabbits; D013501:Surface-Active Agents / Q000494:pharmacology; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014867:Water / Q000378:metabolism
D001055:Apolipoproteins B; D002791:Cholesterol, Dietary; D008055:Lipids; D010743:Phospholipids; D013501:Surface-Active Agents; D014280:Triglycerides; D014867:Water; D011092:Polyethylene Glycols; D011060:Poloxalene; D002784:Cholesterol